12:36 PM EDT, 05/15/2025 (MT Newswires) -- Biofrontera (BFRI) said Thursday it received US patent approval for the revised formulation of Ameluz, extending protection through to December 2043.

Ameluz is a topical gel used in photodynamic therapy to treat actinic keratoses and certain basal cell carcinomas.

Biofrontera is also studying the medicine for the treatment of moderate to severe acne vulgaris. The company said it had enrolled the final patient in the phase 2b clinical trial of the drug, for a total of 120 subjects.

The company anticipates last-patient-out in Q3, it said.

Shares of Biofrontera were up 1.6% in recent trading.

Price: 0.71, Change: +0.01, Percent Change: +1.57